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Abstract
Several studies have revealed a role for neurotrophins in anesthesia-induced neurotoxicity in the developing brain. In this
study we monitored the spatial and temporal expression of neurotrophic signaling molecules in the brain of 14-day-old
(PND14) Wistar rats after the application of a single propofol dose (25 mg/kg i.p). The structures of interest were the cortex
and thalamus as the primary areas of anesthetic actions. Changes of the protein levels of the brain-derived neurotrophic
factor (BDNF) and nerve growth factor (NGF), their activated receptors tropomyosin-related kinase (TrkA and TrkB) and
downstream kinases Akt and the extracellular signal regulated kinase (ERK) were assessed by Western immunoblot analysis
at different time points during the first 24 h after the treatment, as well as the expression of cleaved caspase-3 fragment.
Fluoro-Jade B staining was used to follow the appearance of degenerating neurons. The obtained results show that the
treatment caused marked alterations in levels of the examined neurotrophins, their receptors and downstream effector
kinases. However, these changes were not associated with increased neurodegeneration in either the cortex or the
thalamus. These results indicate that in the brain of PND14 rats, the interaction between Akt/ERK signaling might be one of
important part of endogenous defense mechanisms, which the developing brain utilizes to protect itself from potential
anesthesia-induced damage. Elucidation of the underlying molecular mechanisms will improve our understanding of the
age-dependent component of anesthesia-induced neurotoxicity.
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Introduction
General anesthetics are routinely used in the clinic and their
safety is usually determined by the clinical outcome [1]. Propofol
(2,6-diisopropylphenol) has widespread use as an agent for the
induction and maintenance of anesthesia because of the rapid
onset of its essentially short-acting anesthetic effects and minimal
side effects. However, the molecular mechanisms that underlie the
effects of propofol on neuronal activity remain elusive. Proposed
mechanism of action of propofol in the inhibition of neuronal
activity is based mainly on the activation of gamma-aminobutyric
acid A (GABAA) receptors [2]. Since GABA-mediated neuronal
activity is essential for brain development, it is plausible that
exposure to general anesthetics interferes with normal maturation
and continual behavioral deficits of the brain [3,4].
The neurotrophins are a family of secreted proteins that
mediate numerous functions in both the developing and mature
nervous system, including growth, survival, differentiation and
synaptic plasticity of postmitotic neurons [5]. They are comprised
of the NGF, BDNF, neurotrophin 3 (NT-3) and neurotrophin 4/5
(NT4/5) [6]. Neurotrophins bind the Trk receptors, the members
of a large tyrosine kinase receptor family [6]. BDNF and NGF
exhibit high affinity binding to TrkB and TrkA, respectively [7].
The binding of neurotrophins to Trk receptors induces their
dimerization which is followed by autophosphorylation of tyrosine
residues within the intracellular kinase domain, that leads to the
activation of signaling pathways such as the phosphatidylinositol 3-
kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK)/
ERK pathways [5,8]. Akt and ERK kinases play a crucial role
in regulating various processes in the brain, including neuronal
proliferation, differentiation, development, migration, survival and
long-term synaptic plasticity [9,10]. Phosphorylated Akt can
protect cells from apoptosis via stimulation of the expression of
proteins that favor cell survival and by inhibiting executor caspases
[11,12]. Activation of ERK1/2 generally promotes cell survival,
although under certain conditions, ERK1/2 can possess pro-
apoptotic properties [13]. In our previous study [14], we reported
that short-term propofol anesthesia could have a neurotoxic effect
in the cortex and thalamus of PND7 rats and that this effect is
mediated, at least in part, by neurotrophic downregulation.
In small rodents such as mice and rats, the brain is
underdeveloped at birth, but rapidly matures during the first
weeks of life in a process known as the brain growth spurt [15].
However, the precise timing of regional brain development and
the exact peak of synaptogenesis for each brain region has not
been established. It was shown that rat pups are vulnerable to
anesthesia early in synaptogenesis, that they reach peak vulner-
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stages of synaptogenesis [14,16]. In contrast to PND7 which
are particularly sensitive to the neurotoxic effects of anesthetics,
postnatal day 14 (PND14) being a less vulnerable stage anesthesia-
wise. It is therefore assumed that anesthetics do not exert
neurotoxic effects at this developmental stage [16]. Considering
that short-term propofol anesthesia is widely used in pediatric
practice in all age groups, it is essential to experimentally deter-
mine whether the neurotoxic effects of a single propofol dose are
age-dependent and whether neurotrophic imbalance contributes
to this process.
To this end, we wanted to test the hypothesis whether the
upregulation of pro-survival Akt and ERK kinases was sufficient to
rescue cells from developmentally-regulated anesthesia-induced
neurotoxicity. We expect that the elucidation of Akt/ERK mo-
lecular interaction will help unravel the mechanisms that mediate
propofol-induced signaling in the brain in the later phase of
synaptogenesis. Our results revealed that propofol-induced mod-
ulation of neurotrophins in a region-specific manner initiated
substantial changes in downstream pro-survival kinases, thereby
rescuing cells from neurodegeneration during a critical period of
development.
Results
Propofol treatment differentially affects protein levels of
BDNF in the cortex and thalamus of PND14 rats
To investigate whether propofol treatment affects neurotrophin
signaling, we first monitored the changes in mature BDNF protein
levels in two brain areas involved in anesthetic actions: the cortex
and the thalamus. Western blot analysis revealed a significant
downregulation of mature BDNF protein (14 kDa) in the cortex
(Fig. 1A, *p,0.05), and significant upregulation in the thalamus
after the propofol treatment (Fig. 1B, *p,0.05). A significant
decrease of mature BDNF protein in the cortex was detected at
8 h post-treatment. This trend was sustained until 24 h post-
treatment when a maximal decline was recorded (50%).
In the thalamus, a significant increase was detected at 1 h post-
treatment (2-fold). Moreover, pronounced upregulation of BDNF
levels (more than 10-fold) at time points 4, 16 and 24 h after the
treatment was observed. Statistical analyses revealed a significant
effect of the time after the treatment for the cortex (one-way
ANOVA: F(6, 28)=6.497, p=0.001) and for the thalamus
(Kruskal-Wallis ANOVA: H(6, N=56)=46.671, p=0.001).
Propofol treatment differentially affects protein levels of
total and phosphorylated TrkB in the cortex and
thalamus of PND14 rats
Since BDNF expression was affected by the propofol treatment,
we next examined whether these changes influence the expression
of its respective receptor TrkB. In the cortex, Western blot analysis
did not reveal any significant changes in pTrkB (140 kDa)
expression until 8 h post-treatment when a significant decrease
(by 20–40%) was observed which lasted until the end of follow-up
period (Fig. 2A, *p,0.05). In contrast with the findings obtained
in the cortex, the level of pTrkB protein in the thalamus was
upregulated during the 1–4 h post-treatment period (50–80%)
(Fig. 2C, *p,0.05). However, during the 8–24 h post-treatment
period, the levels of pTrkB were stable, remaining at the control
level. Statistical analyses (one-way ANOVA) revealed a significant
effect of the time after the treatment for both structures (cortex:
F(6, 28)=8.321, p=0.001; thalamus: F(6, 35)=9.474, p=0.001).
In addition, we monitored the expression of total, unpho-
sphorylated TrkB receptor (140 kDa). Unphosphorylated TrkB
receptor was downregulated from 8 to 16 h post-treatment in the
cortex (25–40%) (Fig. 2B, *p,0.05), and only at 8 h post-
treatment in the thalamus (25%) (Fig. 2D, *p,0.05). Statistical
analyses (one-way ANOVA) revealed a significant effect of the
time after the treatment only in the cortex (F(6, 49)=6.524,
p=0.001). In the thalamus, post hoc analyses by the LSD test
revealed a significant effect of the time at 8 h after treatment
(*p,0.05).
Propofol treatment down-regulates NGF protein levels in
the cortex and thalamus of PND14 rats
We also wanted to investigate whether propofol treatment
affects the expression of other neurotrophins such as NGF.
Western blot analysis showed that propofol treatment did not
affect the expression of mature NGF protein (14 kDa) in the cortex
except at 24 h post-treatment when a slight but significant
decrease (by about 20%) was detected (Fig. 3A, *p,0.05).
In the thalamus, decreased levels (20–30%) of mature NGF
protein were detected at all time points except at 2 and 24 h post-
treatment (Fig. 3B, *p,0.05). Statistical analyses (one-way
ANOVA) revealed a significant effect of the time after the
treatment only in the thalamus (F(6, 28)=4.23, p=0.004) and in
the cortex, post hoc analyses by the LSD test revealed a significant
effect of the time at 24 h after treatment (*p,0.05).
Figure 1. Propofol treatment differentially affects mature
BDNF protein levels in PND14 rats. Western blot analysis was
used to determine the expression of mature BDNF in the cortex (A) and
thalamus (B). Graphs that show changes in protein levels are
accompanied by representative immunoblots. The data are expressed
as percentages relative to the respective controls (mean 6 SEM):
*p,0.05 vs. control.
doi:10.1371/journal.pone.0034396.g001
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protein levels in the cortex and thalamus of PND14 rats
Since NGF expression was affected by propofol treatment, we
examined whether this influences the expression of its activated
TrkA receptor. The propofol treatment led to an increase (by 40–
85%) of pTrkA (140 kDa) expression in the cortex (Fig. 4A,
*p,0.05) at 1 to 16 h post-treatment.
In the thalamus, propofol treatment led to a slight increase (by
about 25%) in the level of pTrkA at 1 and 2 h post-treatment
(Fig. 4B, *p,0.05). At 4 to 24 h, the expression of pTrkA was the
same as in the control, albeit a transient decrease was observed at
16 h post-treatment (Fig. 4B, *p,0.05). Statistical analyses (one-
way ANOVA) revealed a significant effect of the time after the
treatment for both structures (cortex: F(6, 42)=7.939, p=0.001;
thalamus: F(6, 35)=14.956, p=0.001).
Propofol treatment differentially affects protein levels of
total and phosphorylated Akt in the cortex and thalamus
of PND14 rats
We next examined by Western blot analysis whether activation
of neurotrophic receptors can influence temporal patterns of total
Akt and activated (phosphorylated) pAkt protein expression. The
propofol treatment did not change the levels of total Akt (56/
60 kDa) in the cortex (Fig. 5A) nor did it affect pAkt (Thr308 and
Ser473) up to 24 h post-treatment. At this time point, decreased
levels of both pAkt (Thr308) and pAkt (Ser473) (by about 25%)
were detected (Fig. 5A, *p,0.05). Regardless of the fact that the
LSD test revealed the significance, one-way ANOVA did not
reveal a significant effect of time after the treatment.
As in the cortex, the propofol treatment did not change the
levels of total Akt protein in the thalamus (Fig. 5B). The levels
of pAkt (Ser473) were unaffected by the treatment as well. In
contrast, a significant increase of pAkt (Thr308) was detected at all
time points after the treatment, with the most dramatic increase
(4–5-fold) observed in the thalamus during the 16–24 h period
after the treatment. Kruskal-Wallis ANOVA revealed a significant
effect of the time after the treatment (H(6, N=21)=18.944,
p=0.004).
Propofol treatment differentially affects protein levels of
total and phosphorylated ERK1/2 in the cortex and
thalamus of PND14 rats
We evaluated by Western blot analysis the levels of total and
phosphorylated ERK1/2 protein (42/44 kDa), one of the main
downstream effector kinases in the neurotrophic signaling pathway.
In the cortex, the propofol treatment did not change the expression
of total ERK1/2 protein (Fig. 6A). In contrast, an increased level of
pERK1/2(2–2.5-fold)wasdetectedinthesamestructureduringthe
8–24 h post-treatment period (Fig. 6A, *p,0.05) (Kruskal-Wallis
ANOVA: H(6, N=35)=26.149, p=0.002).
As in the cortex, the propofol treatment did not change the
expression of total ERK1/2 in the thalamus (Fig. 6B) whereas it
Figure 2. Propofol treatment differentially affects protein levels of total and phosphorylated TrkB in PND14 rats. Western blot
analysis was used to determine the expression of pTrkB and TrkB receptors in the cortex (A and B, respectively) and thalamus (C and D, respectively).
Each graph is accompanied by a representative immunoblot. The data are expressed as percentages relative to the respective controls (mean 6 SEM):
*p,0.05 vs. control.
doi:10.1371/journal.pone.0034396.g002
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during the 2–4 h post-treatment period (Fig. 6B, *p,0.05).
Thereafter, phosphorylation of ERK1/2 returned to the basal
level (One-way ANOVA: F(6, 21)=5.732, p=0.001).
Propofol treatment did not induce neurodegeneration
despite the presence of the caspase-3 active fragment in
the cortex and thalamus of PND14 rats
To determine whether the changes in neurotrophin signaling
that were induced by the propofol treatment influence cell survival
in our experimental model, we examined the expression of cleaved
caspase-3, which served as a marker of apoptosis. Western blot
analysis showed that in the cortex, the propofol treatment induced
the expression of caspase-3 active fragment (17/19 kDa) at 16 h
post-treatment (Fig. 7A). In the thalamus, propofol treatment
stimulated the expression of caspase-3 active fragment (by about
50%) at 8 h after the treatment; this effect was maintained up to
the 16 h time point after which it returned to the control level
(Fig. 7B). Statistical analyses (one-way ANOVA) revealed a
significant effect of the time after the treatment only in the cortex
(F(6, 21)=4.217, p=0.006). In the thalamus, post hoc analyses by
the LSD test revealed a significant effect of the time at 8 and 16 h
after treatment (*p,0.05).
Since Western blot analysis revealed an increase in caspase-3
active fragment in both examined structures at 16 h post-
treatment, we investigated whether neurodegenerative changes are
detectable at the histological level at 8, 16 and 24 h after the
propofol treatment. To this end, we stained sections with Fluoro-
Jade B. Along with Fluoro-Jade B, the sections were labeled with
the nucleic acid stain Hoechst 33258. As a positive control, we
used PND7 rats that were treated with two i.p. doses (0.5 mg/kg)
of (+) MK-801 and killed 24 h after the first administration of the
drug (Fig. 7C, last row). Fluoro-Jade B positive cells were not
detected in the cortex and the thalamus either in control (Fig. 7C,
1st and 3rd row, respectively) or in brain slices from treated rats
(Fig. 7C, 2nd and 4th row, respectively). Furthermore, in order to
determine what dose of propofol in PND14 rats promotes cell
death, we performed independent Fluoro-Jade B experiments on
rats that were separated into five groups: control, treated with the
following doses of propofol – 25, 50, 75, 100 mg/kg. The rats were
killed 16 h post-treatment. We did not find any degenerating
neurons in the cortex and thalamus in any of the examined groups,
except in the group treated with a 100 mg/kg dose of propofol
where we observed only one degenerating cell per examined
structures (data not shown).
Discussion
Following administration of a single dose of propofol, we
examined the temporal and spatial expression of neurotrophins
Figure 4. Propofol treatment up-regulates phosphorylated
TrkA protein levels in PND14 rats. Western blot analysis was used
to determine the expression of pTrkA in the cortex (A) and thalamus (B).
Graphs that show changes in protein levels are accompanied by
representative immunoblots. The data are expressed as percentages
relative to the respective controls (mean 6 SEM): *p,0.05 vs. control.
doi:10.1371/journal.pone.0034396.g004
Figure 3. Propofol treatment down-regulates mature NGF
protein levels in PND14 rats. Western blot analysis was used to
determine the expression of mature NGF in the cortex (A) and thalamus
(B). Graphs that show changes in protein levels are accompanied by
representative immunoblots. The data are expressed as percentages
relative to the respective controls (mean 6 SEM): *p,0.05 vs. control.
doi:10.1371/journal.pone.0034396.g003
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respectively) and downstream kinases (Akt and ERK) in the cortex
and in the thalamus of PND14 rats, two brain areas involved in
the actions of anesthetics. The obtained results show that marked
changes in the levels of the examined neurotrophins, their re-
ceptors and downstream effector kinases that were induced by the
treatment, were not associated with increased cell death in the
cortex and thalamus.
In this study, the changes in mature BDNF protein expression
were region-specific and dynamically modulated during the
first 24 h after a single propofol treatment. We observed a robust
propofol-induced increase in mature BDNF protein in the thal-
amus of PND14 rats. This contrasts the results obtained in PND7
rats, in which thalamic levels of BDNF were reduced by same
propofol treatment (Pesic et al., paper in preparation) or by
anesthesia cocktail containing midazolam, isoflurane and nitrous
oxide [17]. Increase in the mature BDNF protein in the thalamus
of PND14, but not PND7 rats could also be explained by the
retrograde transport of mature BDNF [18]. BDNF can also be
transported anterogradely in the CNS and therefore acts as both a
target-derived neurotrophic factor and an autocrine/paracrine
modulator [19]. In contrast to the thalamus, the levels of mature
BDNF protein appear to be downregulated in the cortex. This is in
agreement with other rodents studies where propofol treatment led
to downregulation of BDNF in the parietal cortex [20]. BDNF
transcription and secretion is known to depend on the release of
Ca
2+ from intracellular depots [21–23]. Since propofol influences
Ca
2+ homeostasis [24] it is thus plausible that the differences in the
expression of BDNF protein in the thalamus and the cortex are
due to their differential sensitivity to the propofol-induced Ca
2+
flux. Altogether, our result could point to fast BDNF turnover
related to redistribution to, and from, different brain regions in the
case of the cortex and thalamus, respectively. We can assume that
propofol treatment rapidly regulates BDNF at posttranslational
level, but this process needs to be further investigated.
The propofol-induced decrease in the levels of mature BDNF in
the cortex (observed 8–24 h period after the treatment) was
accompanied by decreased expression of phosphorylated TrkB
receptor. On the other hand, the increased expression of mature
BDNF in the thalamus (at all experimental time points), was
accompanied by increased expression of pTrkB only during the 1–
4 h period after the treatment but not at other times. In addition,
Figure 5. Propofol treatment differentially affects protein
levels of total and phosphorylated Akt in PND14 rats. Western
blot analysis was used to determine the expression of Akt and pAkt
(Thr308 and Ser473) kinase in the cortex (A) and thalamus (B). Each
graph is accompanied by representative immunoblots. The data are
expressed as percentages relative to the respective control (mean 6
SEM): *p,0.05 vs. control.
doi:10.1371/journal.pone.0034396.g005
Figure 6. Propofol treatment differentially affects protein
levels of total and phosphorylated ERK1/2 in PND14 rats.
Western blot analysis was used to determine the expression of ERK1/2
and pERK1/2 kinase in the cortex (A) and in the thalamus (B). Each
graph is accompanied by representative immunoblots. The data are
expressed as percentages relative to the respective control (mean 6
SEM): *p,0.05 vs. control.
doi:10.1371/journal.pone.0034396.g006
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34396Figure 7. Propofol treatment did not induce neurodegeneration even with detected caspase-3 active fragment in PND14 rats.
Expression of the caspase-3 active fragment in the cortex (A) and thalamus (B). The data are expressed as percentages relative to the respective
control (mean 6 SEM), *p,0.05 vs. control. (C) Fluoro-Jade B staining (left panel), Hoechst 33258 staining (middle panel) and merged images (right
panel) of representative brain sections of the cortex and the thalamus from control-(1
st and 3
rd row, respectively) and propofol-treated (16 h) (2
nd and
4
th row, respectively) PND14 animals. PND7 rats that served as a positive controls were treated with two i.p. doses (0.5 mg/kg) of (+) MK-801 and
killed 24 h after the first administration of the drug. Degenerating neurons are marked with arrows and blood vessels with arrowheads. Scale
bar=20 mm.
doi:10.1371/journal.pone.0034396.g007
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shown that pTrk receptors accumulate in cell bodies and in
proximal axons of sympathetic and sensory neurons after exposure
to neurotrophins [25–27]. Therefore, the results obtained in our
study suggest that in PND14 brains, the alterations in BDNF
expression induced by propofol treatment were probably extra-
cellular. It is for this reason that the appropriate modulation
in TrkB phosphorylation (activity) could be detected. We also
examined the treatment-induced changes in total, unphosphory-
lated TrkB receptor. We observed the downregulation of total
TrkB receptor during the 8–16 h period after treatment, while in
the thalamus decreased expression of the receptor was detected
only at 8 h post-treatment. Thus, in the light of the results
obtained for BDNF and TrkB receptors (both total and phos-
phorylated), it can be hypothesized that the slight decrease in
BDNF level mostly triggers rapid changes in receptor number,
while a robust increase in BDNF level is mostly related to
modifications in receptor activity. Moreover, we think that the
results obtained in the thalamus clearly show how a system defends
itself from excessive ligand levels and prolonged receptor acti-
vation. This was expected considering the important roles that
BDNF assumes during early postnatal development.
As for the other investigated neurotrophin, we detected
downregulation of mature NGF in both examined brain struc-
tures. While the levels of mature NGF decreased, TrkA receptor
was hyperphosphorylated in both the cortex and the thalamus.
Thus, in our experimental model, the changes in NGF expression
did not appear to alter the activity of the TrkA receptor as was
shown previously [28]. However, in vitro studies have shown that in
addition to NGF, other ligands can phosphorylate TrkA receptor,
and that auto-activation of TrkA in the absence of ligands is
possible as well [8,29]. Therefore, it would appear that propofol-
induced changes in NGF and pTrkA in the cortex and thalamus of
PND14 rats could be explained, but comprehensive molecular
analysis is necessary to elucidate the details of these events.
Akt is a well-known cellular pro-survival kinase that acts
downstream from neurotrophin receptors [30,31]. In response to
growth factors, Akt is phosphorylated at two major sites: Thr308
and Ser473 [31–33]. We observed that after propofol treatment,
pAkt Thr308 is downregulated in the cortex and upregulated in
the thalamus. This roughly parallels the propofol-induced changes
in mature BDNF and pTrkB receptor. Surprisingly, changes in
pAkt Ser473 were observed only in the cortex, with downregu-
lation at the same time point when the level of pAkt Thr308 was
decreased. Together with the finding that the treatment did not
induce changes in total Akt level in both examined structure, our
results imply that the propofol-induced changes were related to
modified kinase activity. While only two studies investigated
changes in pAkt level after the administration of an anesthetic to
the developing rats [14,17], they did not examine the phosphor-
ylation of both sites. It remains to be investigated why in the cortex
decreased phosphorylation of Thr308 was followed by decreased
phosphorylation of Ser473, while in the thalamus increased
phosphorylation of Thr308 was not followed by the same mod-
ifications on Ser473. Since Akt is one of the major regulators of
many important cellular functions, it is possible that partial Akt
phosphorylation serves to protect the system from hyperpho-
sphorylated and over-activated Akt kinase, which could ultimately
have deleterious consequences [34].
In addition to Akt, ERK critically influences cell survival and
acts as an effector of neurotrophin signaling [35]. The influence of
propofol on ERK phosphorylation has been mainly examined in in
vitro studies and the obtained results are contradictory [36–38].
Our study showed that pERK1/2 is upregulated in the cortex and
downregulated in the thalamus of PND14 rats upon propofol
administration in a time-dependent manner. Increased pERK in
the cortex could result from propofol-induced activation of pTrkA
receptor. It has been suggested that TrkA internalization is a key
event for sustained ERK signaling in PC12 cells [39], and that
sustained activation of MAPK activity is a distinguishing feature of
neurotrophin signaling [40]. As for the thalamus, we propose that
the observed changes in pERK1/2 are the consequence of
propofol-induced modulation of Akt signaling. It has been
demonstrated that Akt inhibits ERK [41–43]. To date, reciprocal
regulation of Akt and ERK proteins by propofol has not been
observed in vivo.
Several studies in which anesthesia were administered at earlier
developmental stages (P0–P10) have reported that general
anesthetics downregulate the expression of neurotrophins, leading
to subsequent neuroapoptosis [14,17]. In contrast, we monitored
the effects of propofol treatment in PND14 animals when GABA
depolarizing-to-hyperpolarizing shift has already occurred [44,45].
While the active caspase-3 fragment was detected in both
examined structures, we did not observe neurodegeneration at
the histological level. This is most likely due to the effects of
propofol treatment on Akt and ERK1/2 in the thalamus and
cortex, respectively. In turn, these pathways could stimulate anti-
apoptotic proteins such as X-linked inhibitor of apoptosis protein
(XIAP) which binds and inhibits activated caspase-3 [46], as was
recently demonstrated in PC12 cells [47]. Although caspase-3 is
often used as a marker of apoptosis, the activation of apoptotic
proteases can occur transiently and in the absence of cell death.
Apoptotic biochemical cascades can exert local actions and serve
physiological roles such as sculpting neuritic architecture and
synaptic connectivity in developing and in mature nervous system
[48]. In addition, it has recently been shown that propofol can
attenuate the isoflurane-induced caspase-3 activation in vivo and in
vitro and thus act as neuroprotective agent [49]. Thus, our results
are in agreement with other studies in which general anesthetics
did not exhibit neurotoxic properties [50,51]. Together with the
aforementioned studies, our results suggest that the neurotoxic
effects of general anesthetics largely depend on the developmental
stage of the animal.
In conclusion, this is the first study in which propofol has been
described as an agent that exerts complex effects on neurotrophins
and their downstream signaling pathways in the developing brain.
Our data suggest that the expression of BDNF and NGF is
differentially regulated in response to the propofol treatment and
that the main changes in PND14 rat brain occur via the BDNF
signaling pathway and to a lesser extent via the NGF signaling
pathway. We believe that the overexpression of mature BDNF
observed in our experimental model is not exclusively limited to
neuronal survival, but can also affect other aspects of neural
plasticity (paper in preparation). In addition to the significant
changes in expression of neurotrophins, the treatment induced
changes in Akt and ERK expression in a region-specific manner.
Fluoro-Jade B histochemistry did not reveal neuronal degenera-
tion, despite the observed transient increase in the expression of
the caspase-3 active fragment. The obtained results indicate that in
the brain of PND14 rats the activation of Akt and ERK signaling
are an important aspect of the endogenous defense mechanisms
that protect the developing brain from potential damage. The
balanced expression of these pro-survival kinases in the same brain
region seems to be important for proper output signaling and a
favorable physiological outcome. In light of the previous results
[14], it can be assumed that anesthesia-induced neurotoxicity in
the developing brain is determined by age-dependent peculiarities
in the balance between competing pro- and anti-apoptotic signals.
Propofol-Induced Changes in Neurotrophic Signaling
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standing of the actions of anesthetics in the developing brain in vivo;
they also bare potential clinical implications.
Materials and Methods
Ethics Statement
All experiments were approved by the institutional committee
and the University of Virginia Animal Care and Use Committee,
and were performed in accordance with the Guide for the Care
and Use of Laboratory Animals (National Institute for Health,
Publication No. 85/23).
Animals and Treatment
Fourteen-day-old (PND14) male Wistar rats (average body
weight 40–42 g) were used in all experiments. Animals were treated
with propofol manufactured for i.v. human use (RecofolH). The
formulation contained in addition to the active substance, soybean
oil, purified egg phosphatide, glycerol and sodium hydroxide to
adjust the pH. The ampoules were shaken well and the drug was
used according to the manufacturer’s instructions.
The procedures were designed to minimize the suffering of the
animals and the number of rats used. Rat pups were placed in a
temperature-controlled incubator set to an ambient temperature
of 35–36uC. Animals not intended to be killed immediately after
anesthesia were allowed to recover in the incubator for 1 h and
were returned to their mothers to feed. Loss of the righting reflex
(LRR) served as an indicator of anesthetic-induced unconscious-
ness and sleeping time. The length of time required for LRR was
defined as the time between the injection and the point at which
the animal could no longer successfully perform the righting
response when placed on its back. The times of loss and recovery
of the righting reflex, measured in minutes, were recorded with a
stopwatch. We also used the tail pinching test to examine pain
sensation in the anesthetized animals.
We first performed an independent experiment in order to
obtain the optimal dose of propofol that was capable of inducing
effective anesthesia and which would be used in the main study.
PND14 rats were intraperitoneally injected with 10, 25, 50, 75 and
100 mg/kg of propofol. Animals that received the lowest dose of
propofol (10 mg/kg, i.p.) were sluggish but remained fully awake.
This was the only dose that had no effect on the righting reflex. All
other doses caused loss of the righting reflex within the first couple
of minutes; this was accompanied by the absence of response to
pain stimuli (tail pinch test). The righting reflex was impaired for
about 20, 45, 110, 170 min in rats that were administered 25, 50,
75 and 100 mg/kg doses of propofol, respectively. Propofol doses
of 25 and 50 mg/kg did not cause changes in skin color and
breathing patterns. No animal died during these experiments.
Since the injecting volume was too high for animals that received
propofol at a dose of 100 mg/kg, we did not examine higher doses.
Based on these observations and on our previous studies on PND7
animals, we performed all subsequent experiments with a propofol
dose of 25 mg/kg, which impaired the righting reflex for
2062 min.
Experimental Procedure
PND14 rat pups (n=40) were separated from their mothers and
placed in a temperature-controlled incubator set to an ambient
temperature of 35uC. The animals were randomly divided into
seven groups (n=4 per group) and were administered a bolus
injection of propofol (25 mg/kg, i.p.). The animals were
decapitated at different time points after the treatment (at 0, 1,
2, 4, 8, 16 and 24 h). Animals that were not killed immediately
after the anesthesia were allowed to recover in the incubator for
1 h and were returned to their mothers to feed. The cortex and the
thalamus from both hemispheres were isolated and frozen. Since
small amounts of tissue were isolated per animal, the samples were
pooled (n=4 per group).
For Fluoro-Jade B staining, the animals were divided into four
groups (n=3 per group). Three groups were propofol injected
(25 mg/kg i.p.) and decapitated 8, 16 and 24 h after the
treatment. The last group, the physiological control, was injected
an appropriate volume of saline. Whole brains were isolated from
these animals.
Ventilation, oxygenation and perfusion in pups were not
measured due to technical difficulties; however, the animals were
closely monitored throughout the experiment. All pups appeared
pink, well perfused and with no visible signs of cyanosis. We did
not examine the effect of the vehicle (lipid emulsion) because the
aim of the experiments was to explore the effects of propofol in the
form used clinically on humans, also, it was shown previously that
the lipid vehicle does not have any effect [52–55].
Tissue Preparation
To obtain whole-cell extracts, the tissue was homogenized in 10
volumes of RIPA buffer (50 mM Tris–HCl pH 7.5, 150 mM
NaCl, 1% NP-40, 0.1% SDS, 0.5% Triton X-100, 1 mM EDTA
pH 8.0, 1 mM EGTA pH 7.2) containing protease and phospha-
tase inhibitors. The homogenates were sonicated and centrifuged
at 14 000 g for 30 min at 4uC. The supernatants were collected
and stored at 280uC until use.
Protein concentrations were determined by the bicinchonic acid
micro-protein assay (Micro BCA Protein Assay Kit; Pierce Inc.,
Rockford, USA) with albumin as standard.
Western Blot Analysis
Twenty micrograms of protein extracts were heat denaturized,
separated by 12% SDS polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (Amersham Bioscience,
Otelfingen, Switzerland). The membranes were blocked at room
temperature for 1 h either in 3% bovine serum albumin or in 5%
nonfat dry milk in Tris-buffered saline/0.1% Tween-20 (TBS-T),
followed by incubation for 2 h at room temperature or overnight
at 4uC with primary antibodies diluted in blocking buffer. The
membranes were incubated for 1 h at room temperature with
secondary antibodies in Tris-buffered saline/0.1% Tween-20.
Three washes with 0.3% Tween-20 in Tris-buffered saline were
performed between all steps. All blots were incubated with anti-b-
actin or anti-GAPDH antibodies to correct for any differences in
protein loading.
Immunoreactivity was detected by enhanced chemilumines-
cence (ECL; Amersham Bioscience) after exposure on an X-ray
film. All films were densitometrically analyzed using the
computerized image analysis program ImageQuant 5.0. The
individual samples that were examined were pooled from all of
the animals that belonged to the same group (n=4 per group).
Therefore, for each analyzed protein, five different blots were
densitometrically analyzed. Each blot contained a set of seven
samples that were matched according to the time of decapitation
(0, 1, 2, 4, 8, 16, 24 h after the treatment).
The following antibodies were used in this study: rabbit
polyclonal BDNF (N-20: sc-546), rabbit polyclonal NGF (H-20:
sc-548), rabbit polyclonal Trk B (sc-12), mouse monoclonal p-Trk
A (E-6: sc-8058), rabbit polyclonal Akt1/2/3 (H-136: sc-8312),
rabbit polyclonal p-Akt1/2/3 (Thr-308)-R (sc-16646-R), rabbit
polyclonal p-Akt1/2/3 (Ser-473)-R (sc-7985-R), rabbit polyclonal
ERK 1 (K-23: sc-94), mouse polyclonal p-ERK (E-4: sc-7383),
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(sc-2350), bovine anti-rabbit IgG-HRP (sc-2370). All were pur-
chased from Santa Cruz Biotechnology, Inc., Santa Cruz, USA.
Rabbit polyclonal TrkB (phospho Y816) (ab75173) was from
Abcam, Cambridge, USA; rabbit polyclonal cleaved caspase-3
(Asp175, #9661) was from Cell Signaling Technology, Beverly,
USA; rabbit polyclonal b-actin (A-5060) was from Sigma, Saint
Louis, USA; and rabbit polyclonal anti-mouse IgG-HRP (P0260)
was from DACO, Glostrup, Denmark.
Fluoro-Jade B and Hoechst 33258 staining
The animals (n=3 per group) were killed 0, 8, 16 and 24 h after
the propofol injection. The brains were removed and fixed
overnight at 4uC in 4% paraformaldehyde in phosphate-buffered
saline (PBS). The brains were cryoprotected by three 24 h incu-
bations at 4uC in solutions of increasing sucrose concentration
(10%, 20% and 30%) in PBS. The brains were frozen in
isopentane and stored at 280uC. Every fifth coronal section
(18 mm thick) was taken, mounted on the slides, and allowed to dry
overnight and stored at 220uC. The slides were first immersed in
a basic alcohol solution consisting of 1% NaOH in 80% ethanol,
distilled water and incubated in 0.06% KMnO4 solution for
10 min. The slides were transferred for 10 min to a 0.0001%
solution of Fluoro-Jade B (AG310, Chemicon International,
Temecula, USA) dissolved in 0.1% acetic acid. The slides were
rinsed by three changes of distilled water for 1 min per change.
The slides were than immersed in 0.01% Hoechst 33258 (Acros
Organics, Fair Lawn, USA) staining solution for 10 min and
coverslipped with glycerol.
The tissue sections were examined using an Axio Observer
Microscope Z1 (Zeiss, Jena, Germany) with a filter system suitable
for visualizing fluorescein isothiocyanate (FITC). Cells labeled with
Fluoro-Jade B were observed as individual shiny green spots that
were clearly discernible from the background. The (+) MK-801-
treated PND7 rats from our previous study served as a positive
control. PND7 rats that served as positive controls were treated
with two i.p. doses (0.5 mg/kg) of (+) MK-801 and killed 24 h after
the first administration of the drug.
Statistical analysis
The relative changes in protein levels are presented as
percentages (mean 6 SEM) of the control samples that were
assumed to be 100%. Comparisons between the groups were
performed using one-way ANOVA, followed by the Fisher LSD
test, or by Kruskal-Wallis analysis that was followed by the U-test
for the data sets that did not have a normal distribution (Statistica
version 5.0; StatSoft, Tulsa, USA). Significance was set at p,0.05.
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